SCHEMBL30449999

SCHEMBL30449999

CCOC(=O)c1c[nH]n(-c2nc3ccccc3[nH]2)c1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.61
ALDH1A1 P00352 3/20 0.55
ALKBH3 Q96Q83 5/20 0.51
KDM4E B2RXH2 12/20 0.50
NPC1 O15118 1/20 0.47
LMNA P02545 1/20 0.47
MAPK1 P28482 1/20 0.47
RAB9A P51151 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TDP1 Q9NUW8 2/20 0.47
KDM4A O75164 1/20 0.47
KDM4B O94953 1/20 0.47
POLB P06746 1/20 0.47
ALOX15 P16050 1/20 0.47
CASP1 P29466 1/20 0.47
KDM4D Q6B0I6 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SLC11A2 P49281 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL199471 0.76 MAPT (1.00) MAPTALDH1A1KDM4ELMNAHSD17B10
SCHEMBL1192003 0.75 KDM4E (0.51) MAPTALDH1A1KDM4ENPC1LMNA
SCHEMBL1259728 0.74 MAPT (0.71) MAPTALDH1A1KDM4ENPC1MAPK1
SCHEMBL1260514 0.72 MAPT (0.68) MAPTALDH1A1KDM4ENPC1LMNA
SCHEMBL1192845 0.72 ALDH1A1 (0.55) MAPTALDH1A1ALKBH3KDM4ENPC1
SCHEMBL4296230 0.72 HSD17B10 (0.61) MAPTALDH1A1KDM4ENPC1LMNA
SCHEMBL1260421 0.71 MAPT (0.67) MAPTALDH1A1KDM4ELMNAHSD17B10
SCHEMBL880365 0.71 ALDH1A1 (0.62) MAPTALDH1A1KDM4ENPC1LMNA
SCHEMBL1193289 0.71 EGLN1 (0.68) MAPTALDH1A1NPC1LMNAMAPK1
SCHEMBL9375434 0.71 NOTUM (0.49) MAPTALDH1A1ALKBH3KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11618744-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2023-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11618744-B2 Benzoimidazoles as prolyl hydroxylase inhibitors P4HA1, PAH, EGLN3 MAPT 2583/4885ALDH1A1 46/4885ALKBH3 458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.